GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101
(RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma.
Patients will be randomized to receive either GA101 or rituximab, given as four weekly
infusions. At the conclusion of the initial trial patients may be eligible to continue
therapy up to 24 months. The anticipated time on study treatment is 3- 24 months, and the
target sample size is 100-500 individuals.